Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab on B-cell Tolerance in Relapsing MS
NCT04261790Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Johns Hopkins University. Primary endpoints: Change in Peripheral B-cell Tolerance Checkpoints, Change in B-cell Subpopulations and 3 more. Started Aug 2020; status: completed.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04261790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261790.